Investor Room

Mukoko Studio · Investment brief

Presentation-ready view of opportunity, proof and use of funds. Print for a leave-behind.

Opportunity
Independent UK studios that are founder-led, culturally intelligent and delivery-honest are rare. Mukoko Studio builds the digital work that heritage, public sector and mission-led organisations actually need · accessible platforms, thoughtful identity and practical AI adoption.
Why now
UK councils, arts and cultural bodies are re-tendering digital estates with a stronger emphasis on accessibility and value. Zimbabwean regulators are procuring executive AI and mentoring programmes. Mukoko sits at the intersection of both markets with a live flagship bid and an active pipeline.
Portfolio proof
  • MyDestiny Inc · platform and comms
  • Remit Hope · retained delivery
  • Delta Impact Hub · strategy and build
  • Further Together · programme site
  • AstraZeneca · enterprise product leadership
  • Tulia Group · roadmap and design system
Revenue model
Fixed-fee client engagements, retained delivery, public bids and grant-funded programmes. Productised retainer in development.
Pipeline snapshot
Weighted pipeline
£8,185
Open tender value
£128,900 + 2 TBC
Contracted (illustrative)
£18,750
2026 target
£250,000
Use of funds
Total £12,000
Milestones
  1. Q3 2026: Submit Timespan flagship bid, secure two specialists to bench.
  2. Q4 2026: Convert two speculative engagements to retained delivery.
  3. Q1 2027: Land one Zimbabwe consortium workstream.
  4. Q2 2027: Launch productised retainer to three warm clients.
Risks
  • Founder capacity while public bids run in parallel.
  • Specialist bench maturity for accessibility-critical builds.
  • Reliance on speculative work until retainer product ships.
Founder advantage
Taz Mukoko combines enterprise product leadership (AstraZeneca) with founder-led delivery across heritage, community and diaspora sectors. Culturally intelligent, technically fluent and honest about scope.